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intraductal approaches for ultrasound-
based thermal therapy of the pancreas
Serena J. Scott1, Matthew S. Adams1,2, Vasant Salgaonkar1, F. Graham Sommer3 and Chris J. Diederich1,2*
Abstract
Background: The goal of this study was to theoretically investigate the feasibility of intraductal and transgastric
approaches to ultrasound-based thermal therapy of pancreatic tumors, and to evaluate possible treatment strategies.
Methods: This study considered ultrasound applicators with 1.2 mm outer diameter tubular transducers, which are
inserted into the tissue to be treated by an endoscopic approach, either via insertion through the gastric wall
(transgastric) or within the pancreatic duct lumen (intraductal). 8 patient-specific, 3D, transient, biothermal and acoustic
finite element models were generated to model hyperthermia (n = 2) and ablation (n = 6), using sectored
(210°–270°, n = 4) and 360° (n = 4) transducers for treatment of 3.3–17.0 cm3 tumors in the head (n = 5), body
(n = 2), and tail (n = 1) of the pancreas. A parametric study was performed to determine appropriate treatment
parameters as a function of tissue attenuation, blood perfusion rates, and distance to sensitive anatomy.
Results: Parametric studies indicated that pancreatic tumors up to 2.5 or 2.7 cm diameter can be ablated within
10 min with the transgastric and intraductal approaches, respectively. Patient-specific simulations demonstrated that
67.1–83.3% of the volumes of four sample 3.3–11.4 cm3 tumors could be ablated within 3–10 min using transgastric or
intraductal approaches. 55.3–60.0% of the volume of a large 17.0 cm3 tumor could be ablated using multiple applicator
positions within 20–30 min with either transgastric or intraductal approaches. 89.9–94.7% of the volume of
two 4.4–11.4 cm3 tumors could be treated with intraductal hyperthermia. Sectored applicators are effective in directing
acoustic output away from and preserving sensitive structures. When acoustic energy is directed towards sensitive
structures, applicators should be placed at least 13.9–14.8 mm from major vessels like the aorta, 9.4–12.0 mm from
other vessels, depending on the vessel size and flow rate, and 14 mm from the duodenum.
Conclusions: This study demonstrated the feasibility of generating shaped or conformal ablative or hyperthermic
temperature distributions within pancreatic tumors using transgastric or intraductal ultrasound.
Keywords: Ultrasound, Thermal ablation, Hyperthermia, Pancreas, Theoretical model
Background
Pancreatic cancer is a particularly severe disease, with a
5-year survival rate of about 6% in the United States [1].
It is the fourth most common cause of cancer-related
deaths, causing 39,590 deaths per year in the United
States [1]. Although surgery provides the best chance for
cure [2, 3], most cases have progressed to advanced or
locally advanced disease by the time of diagnosis [4, 5],
and over 80% of patients are not candidates for resection
[2, 5]. For patients who are not surgical candidates, pro-
longation of survival and palliative relief of symptoms
are the major goals of medical treatment [3, 4, 6], with
chemotherapy and radiotherapy as the most common in-
terventions [2, 4]. Palliative care for advanced disease
may include surgery, radiotherapy, biliary stenting, gas-
troduodenal stenting, analgesia, celiac plexus blockage,
and prophylactic anticoagulants to care for conditions
such as pain, jaundice, gastrointestinal obstruction, and
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venous embolism [2, 4, 6]. Thermal ablation has been
shown to cause a reduction in tumor volume, to lower
pain, and in some studies, to prolong survival [5, 7, 8].
Various ablative modalities have been considered for
care of advanced pancreatic cancer, including RF abla-
tion (RFA), microwave ablation, cryoablation, photo-
dynamic therapy, high intensity focused ultrasound
(HIFU), and irreversible electroporation, with HIFU and
RFA receiving the most attention [5]. During thermal
ablation, it is key to preserve sensitive tissues such as
the duodenum and the peripancreatic vasculature, so a
margin of tumor tissue is often left viable [7, 9]. In some
studies, sensitive tissues were flushed with cold saline,
and the vena cava could be covered with wet gauze dur-
ing intraoperative interventions to prevent thermal in-
jury [7, 9]. RFA of pancreatic cancer is usually
performed during open surgery [9], but has also been
performed using endoscopic approaches [10, 11]. The
RF needle can be inserted through the working channel
of an echoendoscope and into the pancreas through the
wall of the stomach or duodenum under ultrasound
guidance [10]. This endoscopic approach is less invasive
than surgical and percutaneous approaches, and hence
should result in fewer complications, but while the
stomach and duodenum could potentially be water-
cooled, this does not allow for active cooling of most
sensitive tissues. Computed tomography (CT), magnetic
resonance (MR), or ultrasound guidance and treatment
monitoring may be applied to improve outcomes and re-
duce complications during thermal ablation [5, 8]. RF
and other ablative therapies can be performed alongside
the placement of biliary or duodenal stents as necessary
to reduce complications and procedure time [5]. HIFU
can be performed completely noninvasively with MR or
ultrasound guidance, though limitations include bowel
gas obstruction of the sonication path, which may pre-
clude treatment of some targets, and the need to com-
pensate for respiratory motion [8].
Endoscopic ultrasound applicators placed in the stom-
ach or duodenum have previously been developed for
thermal ablation of pancreatic tumors, applying either
HIFU [12] or unfocused high intensity ultrasound abla-
tion [13] techniques. Since transgastric and intraductal
probes are advanced into the tumor itself, there are
fewer concerns about breathing artifacts or motion of
the applicator along the stomach wall than with other
endoscopic ultrasound techniques. Transgastric and
intraductal applicators can also access targets farther
from the stomach wall than unfocused endoscopic
probes placed within the stomach or duodenum.
Catheter-based ultrasound ablation is also generally fas-
ter than HIFU, in which a small focal zone is scanned
over the tumor, as the heated region covers a larger
volume [14].
Small-diameter ultrasound applicators with tubular
transducers could potentially allow for thermal therapy
of pancreatic tumors with fewer limitations than HIFU
or RF ablation. Such applicators have been applied in the
past in the prostate, liver, bone, heart, and brain using
catheter or balloon-based cooling, and are in clinical use
for hyperthermia [14–21]. These flexible applicators are
advanced directly into or adjacent to the tissue to be
treated, and achieve 15–21 mm of thermal penetration
within 5–10 min with spatial control along the length
and angle of the applicator [15, 22–24]. For applications
in the pancreas, the ultrasound applicator could be ad-
vanced through the working channel of an echoendo-
scope, then through the stomach wall, duodenal wall,
pancreatic duct, or biliary duct, and directly into the
tumor under ultrasound imaging guidance. Intraductal
ablation can be done using techniques similar to those
applied in prior treatments of the pancreas and biliary
ducts using RFA [25–27] or planar ultrasound applica-
tors [28]. Transgastric ablation could be performed
using techniques similar to those of needle-based RF ab-
lation [29, 30] and catheter-based cryotherm ablation,
which uses a 1.8 mm probe [10, 31]. Sectored ultrasound
transducers can be used for sparing of adjacent sensitive
tissues, by providing directionality that RF, microwave,
and laser ablation lack.
The goal of this study is to apply theoretical models to
evaluate the feasibility of ultrasound-based thermal ther-
apy using endoscopic approaches to deliver interstitial or
catheter-based ultrasound devices specific for this appli-
cation. Theoretical modeling techniques that have been
previously tested and validated broadly in both bone and
soft tissue [16, 17, 32, 33] are applied in this theoretical
study to perform a preliminary investigation. Numerical
models of several patient cases are created to assess vari-
ous approaches, applicator configurations, and treatment
parameters. Both ablation and hyperthermia, which has
been shown to improve the effects of chemotherapy and
radiation in the treatment of pancreatic cancer [34, 35],
are considered. Parametric studies are performed to de-
termine the necessary safety margins for preservation of
major blood vessels and the duodenum, and to investi-
gate the effects of the acoustic absorption coefficient
and blood perfusion rates on treatment outcomes.
Methods
Endoscopic ultrasound devices
The ultrasound applicators considered in this study
are to be deployed through the working channels of
endoscopic probes, which are often up to 3.2 mm
inner diameter (ID) [36]. Two different approaches
are applied: direct insertion of an ultrasound applica-
tor into the tumor through the wall of the stomach
or duodenum, and insertion of a more flexible
Scott et al. Journal of Therapeutic Ultrasound  (2017) 5:10 Page 2 of 16
applicator through the pancreatic duct. This can be
performed using routes commonly employed during
endoscopic ultrasound-guided biopsy and pancreatic
duct stenting, and techniques previously employed for
transgastric ablation of the pancreas [10, 29–31]. Both
hyperthermia and ablation are considered for the
intraductal approach. Only ablation is considered for
the transgastric approach, to balance the risks associ-
ated this slightly more invasive technique with a more
thorough and direct treatment.
Both types of applicators consist of 2–3 tubular ultra-
sound transducers (7 MHz; 1.2 mm outer diameter
(OD); 7.5, 10, or 15 mm long) mounted on the distal tip
of an applicator. This device configuration is modeled
after those commonly used in similar interstitial ultra-
sound applicators [14, 33, 37], with a slightly smaller
diameter to minimize damage to the stomach wall and
for easier maneuverability within the pancreatic duct.
These transducers, which radiate radially outward, can
be sectored to attain directional control of the acoustic
output, such that the transducers radiate only to one
side [37]. 210°, 270°, and 360° active sectors were consid-
ered in this study. The applicators are water-cooled for
acoustic coupling and to prevent thermal damage to the
transducers.
The transgastric applicators are inserted into the
tumor through the stomach or duodenal wall, and are
deployed within a water-cooled catheter (Fig. 1a),
similar to catheter-based ultrasound applicators de-
signed for percutaneous insertion [37, 38]. The plastic
catheter (1.6 mm ID, 2.11 mm OD) around the trans-
gastric applicator is modeled after the cooling flow
lumen and wall thicknesses of catheters for interstitial
applicators [39, 40], and is assumed to have an ultra-
sound attenuation coefficient of 43.9 Np/m/MHz [39].
Intraductal applicators would be advanced through
the biliary or pancreatic duct in order to access the
tumor. The transducers are surrounded by a single
distensible water-cooled balloon (2.2 mm OD, 12.7 μm
thick, Fig. 1b), similar to that used in transurethral
prostate ablation [41]. The applicator is designed to
be small enough to fit within the duct [42] while
maintaining a layer of cooling water around the trans-
ducers. It is similar in size to pancreatic stents [43]
and, when uninflated, intraductal ultrasound imaging
probes [44]. The balloon around the intraductal appli-
cator is assumed to be so thin as to cause negligible
acoustic attenuation.
Acoustic and biothermal simulations
Heat transfer through physiological tissues was modeled
using Pennes bioheat equation [45]:
ρc
dT
dt
¼ ∇⋅k∇T− ωcb T−Tbð Þ þ Q ð1Þ
where ρ is density (kg/m3), c is specific heat (J/kg/°C), T
is temperature (°C), t is time (s), k is thermal conductiv-
ity (W/m/°C), ω is the blood perfusion rate (kg/m3/s), Q
is the heat deposition due to ultrasound (W/m3), the
subscript b refers to blood, and capillary blood
temperature Tb is assumed to be 37 °C. To approximate
the effects of heating-induced microvascular stasis,
which occurs at a thermal dose of around 300 EM43°C
[16], blood perfusion rates in all tissues were assumed to
reduce to zero at a temperature of 54 °C, which was
found in this computational study to correspond to 300
EM43°C at the acoustic intensities and durations typic-
ally applied. The material properties of the various tis-
sues considered are specified in Table 1.
Tissues that reached 52 °C were considered to be ab-
lated [46], and hyperthermia simulations were performed
with an aim of maintaining temperatures of 40–47 °C
throughout the target volume. Sensitive tissues, includ-
ing the stomach wall, intestines, blood vessels, liver, kid-
neys, spleen, and bones, were to be kept below a safety
threshold of 45 °C [47].
The acoustic heat deposition from a tubular ultra-
sound source can be modeled as a radially radiating
Fig. 1 Diagram of transgastric (a) and intraductal (b) applicators for ultrasound-based thermal therapy of the pancreas. Transgastric applicators
are operated from within a water-cooled catheter (1.6 mm ID, 2.11 mm OD), while intraductal applicators have a thin water-cooled balloon
(2.2 mm OD) around the transducers. 2–3 transducers can be mounted on each applicator, with an outer diameter of 1.2 mm and a length of 7.5,
10, or 15 mm
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intensity profile well-collimated to the length and sector
angle of the transducer [33, 41]:
Q ¼ 2αIs rtr e
−2
Z
rt
r
μdr
0
ð2Þ
where α is the ultrasound absorption coefficient (Np/m),
Is is the acoustic intensity on the transducer surface
(W/m2), rt is the transducer radius (m), r is the radial
distance from the central axis of the transducer (m),
and μ is the ultrasound attenuation coefficient (Np/m).
The ultrasound absorption coefficient is assumed to be
equivalent to the ultrasound attenuation coefficient, with
scattered energy locally absorbed.
Heat transfer in tissue was modeled using COMSOL
Multiphysics 4.4 (COMSOL, Inc., Burlington, MA) in
conjunction with MATLAB (Mathworks, Inc., Natick,
MA). An initial tissue temperature of 37 °C was assumed
for all simulations. A Dirichlet boundary condition con-
strained the outermost boundaries of the tissue volume,
far from the heated region, to 37 °C. Blood flow through
larger vessels [48], as well as water cooling of the cath-
eter and balloon, are modeled using convective bound-
ary conditions:
−n^⋅ −k∇Tð Þ ¼ h Tf −T
  ð3Þ
where n^ is the unit vector normal to the vessel, catheter,
or balloon surface, h is the heat transfer coefficient
(W/m2/°C), and Tf is the fluid temperature, as speci-
fied in
Table 2. To simplify the modeling of the vessels in the
patient-specific study, which had non-constant diameters
and complex geometries, the vessels were assigned a
heat transfer coefficient based on size and flow rate.
Unique heat transfer coefficients were calculated for the
aorta and vena cava. In the remaining vasculature the
heat transfer coefficient was calculated to be approxi-
mately 750 W/m2/°C for large vessels such as the portal
vein, superior mesenteric vein, etc., and 1000 W/m2/°C
for smaller vessels such as the splenic artery, superior
mesenteric artery, hepatic artery, etc.
Convergence tests were performed to select mesh sizes
and time steps small enough for accuracy. The finite
element mesh size was limited to a maximum of
0.45 mm on the applicator, and no more than 7–7.5 mm
overall, with a finer mesh on highly heated volumes, a
Table 1 Material properties of tissues. ƒ represents frequency, in units of MHz
Medium Density (kg/m3) Attenuation (Np/m) Thermal conductivity (W/m/K) Specific heat (J/kg/K) Perfusion rate (kg/m3/s)
Tumor 1050a 10 ƒ [52, 65] .51a 3200a 4.5 [51, 66–68]
Pancreas 1050 [52] 11.9 ƒ0.78 [52] .51 [52] 3200 [69] 10 [52]
Duodenal wall 1050 [52] 5 ƒ .53 [52, 69] 3700 [69–71] 16.7 [52, 69]
Stomach wall 1060 [52, 69] 5 ƒ .54 [52, 69] 3700 [69] 6.8 [52, 69]
Water, pancreatic juices,
and gastric contents
1010 [52, 72] 0.025 ƒ2 [52] .58 4000 0
Blood N/A 1.6 ƒ1.21 [52] N/A 3600 [52] N/A
Liver 1050 [52] 4.5 ƒ [16] .51 [52] 3600 [16] 15 [16]
Kidney 1050 [52] 6 ƒ [52] .54 [52] 3700 [52] 68.9 [52]
Spleen 1050 [52] 13.2 ƒ [52] .54 [52] 3700 [52] 22.1 [52]
Bone 1420 [52] 105 ƒ [52] .38 [52] 1700 [73] 0.89 [74]
Renal calcifications 1990 [52]b 105 ƒ [52]b .5 [52]c 1300 [52]b 0
Bowel 1040 [52] 5.6 ƒ [52] 0.56 [52] 3600 [69] 16.4 [52]
Other soft tissue 1050 [52] 6.4 ƒ [52] .49 [52] 3400 [52] 3 [52]
Properties of normal pancreatic tissue were used for some pancreatic tumor properties (a). The acoustic attenuation of various neoplasms was used to estimate
the attenuation in pancreatic tumors. Because the specific heat of water is very different from those of tissue and biological fluids, an intermediate value was used
for the specific heat of water, pancreatic juices, and gastric contents. Attenuation of the stomach and duodenal walls were estimated from measurements
performed in porcine stomach tissue. Properties for whole or cortical bone (b) were used for some calcification properties, and properties for calcified arterial
plaques were used for another (c)
Table 2 Heat transfer coefficients and fluid temperatures for
convective flow boundaries
Surface h (W/m2/°C) Tf (°C)
Transgastric catheter 1000 [16, 75] 22
Intraductal balloon 500 [13, 63] 22
Aorta 511 37
Vena cava 184 37
Large vessels 750 37
Small vessels 1000 37
Heat transfer coefficients for blood vessels are calculated based upon vessel
sizes, which were measured in CT scans, and flow rates [76–82] as described
by Haemmerich et al. [48]. “Large vessels” included the portal vein, superior
mesenteric vein, etc. “Small vessels” included the superior mesenteric artery,
splenic artery, hepatic artery, etc
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wider mesh on the outer tissue boundaries, and gradual
transitions in mesh size over space. An implicit transient
solver with variable time stepping was used in ablation
simulations as necessary in order to track the dynamic
spreading of high temperatures over short treatment in-
tervals. Initial time steps were small (<1 s), and gradually
increased automatically to no more than 15 s as the so-
lution converged. When determining the amount of time
it takes for sensitive tissue to heat to dangerous temper-
atures in parametric studies, maximum time steps were
limited to 2–15 s at time points when the tissue was ex-
pected to approach the temperature threshold. Hyper-
thermia distributions were calculated using a steady-
state solver under steady-state conditions, which assume
that target temperatures are achieved within a short
interval and maintained for a typical 30–60 min treat-
ment session.
Patient-specific models
To investigate approaches for transgastric and intraduc-
tal thermal therapy using tubular ultrasound transduc-
ers, eight 3D patient-specific models were developed.
The 3D models were made by segmenting CT scans and
then creating 3D finite element meshes based on indi-
vidual patient anatomies (Fig. 2). Individual organs and
structures, including tumors and blood vessels, were
identified. Applicator positions and treatment parame-
ters were selected using an empirical, iterative approach
to maximize tumor coverage without damaging sensitive
anatomy. Finite element modeling was performed to cal-
culate temperatures throughout the tissue volume. Abla-
tion was modeled using time-dependent simulations,
with a proportional integral (PI) controller to determine
applied powers, while hyperthermia was modeled at
steady state, with constant powers selected empirically.
To create the models, CT scans of six patients with tu-
mors (1.9–4.8 mm long along the applicator axis, 3.3–
17.0 cm3, Table 3) in the head (n = 4), body (n = 1), or
tail (n = 1) of the pancreas were segmented using a
combination of manual and semi-automatic techniques.
Note the UCSF Internal Review Board (IRB) considers
the use of de-identified data (images used herein) with-
out a key back to the subject as “Not Human Subjects
Research”, and does not require approval. All organs
near each target were selected for segmentation, and
could include the tumor, pancreas, pancreatic duct (if
visibly distended), duodenal wall, stomach wall, gastro-
intestinal contents, liver, kidney, spleen, vertebrae, and
bowel. Thermally significant blood vessels, such as the
aorta, vena cava, portal vein, superior mesenteric vein,
splenic vein, renal veins, and superior mesenteric artery,
were also segmented. Image segmentation and finite
element mesh generation were performed using the
Mimics Innovation Suite (Materialise NV, Leuven,
Belgium), as illustrated in Fig. 2. The finite element
mesh was imported into COMSOL Multiphysics, where
acoustic and thermal modeling of ablation and/or hyper-
thermia was performed.
An iterative approach was employed for each patient
case to determine appropriate treatment parameters,
such as applicator position, transducer length, trans-
ducer sector angle, power, and treatment time. Power
levels for hyperthermia were empirically selected to raise
a maximum volume of the tumor to 40–47 °C while
maintaining critical anatomy, such as the duodenum and
blood vessels, under 45 °C. In transient ablation simula-
tions, a PI controller (kp = 0.375 W/°C, ki = 0.003 W/°C/s)
was used to maintain maximum temperatures in the
tumor volume of 80 or 85 °C, with a lower target
temperature used in cases with longer treatment durations
and in cases with sensitive tissues in proximity to the most
heated regions. For clinical implementation of such a con-
troller, temperature measurements from MR temperature
imaging or needle-based temperature probes could be
employed. Ablation treatments, which were simulated
using a time-dependent model, were considered complete,
and treatment was ended, when the full tumor volume
reached a lethal temperature of 52 °C, or when sensitive
Fig. 2 Process used for creation of 3D patient-specific models
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anatomy to be preserved neared 45 °C, whichever came
first.
Transgastric approaches were modeled in cases with
an available insertion path from the stomach or duode-
num to the tumor that did not transverse any sensitive
anatomy. Intraductal approaches were modeled in cases
in which most of the tumor volume was within 1.5 cm
of the pancreatic or bile duct. In cases in which the
tumor is on one side of the bile duct, a transgastric ap-
plicator can be placed through the center of the tumor,
and an intraductal applicator can use sectored transduc-
ers to heat to one side. However, the far side of a tumor
adjacent to the duct may be too far from an intraductal
applicator for it to be treated effectively, so for this rea-
son, the tumors considered in Cases 6 and 8 were mod-
eled only with a transgastric approach. To simulate
realistic applicator positions as delivered through the
working channel of an endoscope, the transgastric appli-
cators were inserted through the stomach or duodenal
wall at an acute angle to the tangent plane of the wall.
In Cases 1, 2, and 8, in which the stomach or duodenum
was close to the targeted volume and in danger of ther-
mal damage, the stomach and duodenum were assumed
to be filled with 22 °C cooling water 2–5 min before
treatment began. This cooling was modeled using an ini-
tial temperature condition within the stomach and duo-
denum of 22 °C, and an initial temperature of 37 °C
elsewhere.
Hyperthermia was considered only for tumors near
the duodenum that could be treated intraductally using
a single applicator position. To warrant the invasiveness
of a transgastric approach, only the aggressive treatment
of ablation was considered for such cases. The tail of the
pancreas was judged to be too far from the duodenum
to be accessed endoscopically through the pancreatic
duct. To be treated with hyperthermia, which lasts on
the order of an hour, the tumor also had to be small
enough to treat the full volume using a single applicator
position, as multiple positions would require excessive
amounts of time.
Parametric studies
Parametric studies were performed to investigate neces-
sary treatment parameters as a function of distance from
critical blood vessels, distance from the duodenum, the
acoustic absorption coefficient, and blood perfusion
rates. Simple geometric models and meshes were created
in COMSOL to represent the various tissues, with the
same meshing and modeling parameters as the patient-
specific models. The applicator was positioned in the
center of a large cylinder of soft tissue. A PI controller
(kp = 0.375 W/°C, ki = 0.003 W/°C/s) was used to main-
tain maximum tissue temperatures of 80 °C.
Parametric studies of preservation of blood vessels
A wide variety of critical blood vessels are in close prox-
imity to the pancreas, including but not limited to the
aorta, the vena cava, the portal vein, the superior mesen-
teric vein and artery, the splenic vein and artery, the
renal veins and arteries, the common hepatic artery, the
right gastroepiploic vein, the celiac artery, and the left
gastric artery. A parametric study was performed to
evaluate the effect of any errors in estimation of the heat
transfer coefficients of the vessels and to determine the
distance between the applicator and the vessels neces-
sary for the vessels to be fully preserved (T < 45 °C).
In these 3D models, the blood vessels were repre-
sented by an 8 cm high tube oriented parallel to the ap-
plicator (Fig. 3a). The transgastric applicator considered
had two 1 cm long, 360° transducers, which were posi-
tioned in the center of a 12 cm OD, 8 cm high cylinder
of tissue surrounding both the applicator and the vessel
Table 3 Treatment parameters for patient-specific cases
Case Tumor
location
Tumor length
(cm)
Tumor volume
(cm3)
Approach Treatment Applicator
configuration
Treatment time
(min)
Mean power
(W)
% volume
treated
1 Body 4.8 17.0 Transgastric Ablation 2x10 mm, 270° 20 10.1–11.9 60.0
2 Body 4.8 17.0 Intraductal Ablation 2x10 mm, 210° 30 8.8–11.6 55.3
3 Tail 1.9 3.3 Transgastric Ablation 2x7.5 mm, 270° 10 13.3 72.7
4 Head 1 2.5 4.4 Intraductal Hyperthermia 2x15 mm, 360° N/A 3.8 89.9
5 Head 1 2.5 4.4 Intraductal Ablation 2x15 mm, 360° 8 9.7 83.3
6 Head 2 2.0 4.4 Transgastric Ablation 2x10 mm, 360° 9 10.5 81.6
7 Head 3 3.9 11.4 Intraductal Hyperthermia 3x15 mm, 360° N/A 3.5 94.7
8 Head 4 3.2 7.9 Transgastric Ablation 2x15 mm, 270° 10 10.0 67.1
Four different tumors in the head of the pancreas were modeled, and are numbered. Tumor length is defined as the tumor dimension along the applicator axis.
The applicator configuration gives the number of transducers, the length of the transducers, and the sector size. Regions over 52 °C for ablation and 40 °C for
hyperthermia are considered to be treated. Powers for Cases 1 and 2 were adjusted at each applicator position. Power for each time-dependent ablation study
was varied continuously by a PI controller, so mean power is reported. Hyperthermia treatments were modeled as steady-state simulations, so a single value for
power was simulated, and a specific treatment time is not applicable
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(Fig. 3a). The aorta and vena cava were represented by
18 mm ID, 22 mm OD hollow cylinders; large vessels
such as the portal vein by 11 mm ID, 13 mm OD hollow
cylinders, and small vessels such as the superior mesen-
teric artery by 5 mm ID, 5.8 mm OD hollow cylinders.
The distances between the vessels and the applicators
reported in this study are measured from the outer sur-
face of the vessel to the center of the applicator.
A wide variety of heat transfer coefficients, ranging
from 46 or 184 kg/m3/s up to 1500 or 3000 kg/m3/s,
were applied for each vessel size bracket in this paramet-
ric study. The range considered is far wider than the
heat transfer coefficients calculated for the vessels in
each size grouping. Such a wide range is modeled so that
the effects of vessel size on temperature can be observed
as a function of the heat transfer coefficient.
Parametric study of duodenal heating
Because the pancreas is in such close proximity to the
stomach and duodenum, a parametric study was per-
formed to assess techniques for preserving these tissues.
As most tissue properties are similar for these two mate-
rials, and the majority of pancreatic tumors arise in the
head of the pancreas [6] which is near the duodenum,
heating of the duodenum was modeled in this study.
The effects of the distance from the applicator to the
duodenum, the use of sectored transducers, and water-
cooling of the duodenum on the peak temperatures gen-
erated in the duodenum were evaluated. 360° and 270°
sector angles were considered, with the 270° sectors di-
rected away from the duodenum. The applicator was
placed 2–30 mm from the duodenum, as measured from
the center of the applicator to the outer surface of the
duodenal wall. To water-cool the duodenum, it was
assumed that the duodenal lumen was filled with 22 °C
water immediately before heating began, and that the
water was left in the duodenum and gradually warmed
by the surrounding tissue. In cases without cooling, the
initial temperature of the duodenal lumen was assumed
to be 37 °C. In cases with cooling, the duodenal lumen
was assumed to have an initial temperature of 22 °C,
and all surrounding tissues were assumed to have an ini-
tial temperature of 37 °C.
In these 3D models, a transgastric applicator with two
1 cm long transducers was positioned in the center of a
large cylinder of tissue (8 cm high, 12 cm diameter).
Two concentric 8 cm high cylinders parallel to the appli-
cator represented inner and outer surfaces of the duode-
num, which was assumed to have an outer diameter of
25 mm (Fig. 3b) [49]. Duodenal wall thickness has been
reported as 1.5–3 mm [49, 50], so a wall thickness of
3 mm was assumed to avoid underestimation of duo-
denal heating. The contents of the duodenum were
modeled as water.
Parametric study of absorption and perfusion
As the acoustic properties and blood perfusion rates of
pancreatic tumors have not been widely reported in the
literature, a parametric study was performed to evaluate
the effects of ranges of acoustic attenuation and blood
perfusion rates on ablation outcomes. The maximum le-
sion diameter (T > 52 °C) was calculated for a variety of
tissue attenuations (35–85 Np/m at 7 MHz) and perfu-
sion rates (0–10 kg/m3/s), ranges chosen to encompass a
variety of recorded tumor perfusion rates [51], necrotic
tumor cores, and a variety of attenuation values com-
mon in healthy and cancerous soft tissues [52]. All other
material properties for pancreatic tumors were set to
Fig. 3 Diagram of geometries of parametric studies, showing the applicator in the center of a cylinder of tissue. Geometries for studies of blood
vessel and duodenal heating include two concentric cylinders representing the inner and outer surfaces of a blood vessel (a) or duodenal wall
(b). In 2D studies of the impacts of attenuation and perfusion, the temperature distributions in the axisymetric geometry was rotated about the
central axis to represent a 3D cylinder (c)
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those of pancreatic tissue, as shown in Table 1. An appli-
cator with two 15 mm long 360° transducers was consid-
ered. It was placed with the transducers in the center of
a 9 cm high, 5 cm radius cylinder of tissue (Fig. 3c), and
heating was performed for 10 min, considering both
transgastric and intraductal applicators.
Results
Patient-specific models
Hyperthermia and/or ablation treatments of 6 pancreatic
tumors were simulated using intraductal and/or trans-
gastric approaches. Four tumors were in the head of the
pancreas, one was in the body, and one was in the tail.
Eight treatments were simulated: four intraductal and
four transgastric approaches, with six ablations and two
hyperthermia treatments. The tumor sizes, treatment pa-
rameters, and treatment outcomes for the 8 cases are
summarized in Table 3. 67.1–83.3% of the volumes of
four small and medium-sized tumors (3.3–7.9 cm3)
could be ablated within 10 min using one applicator
position. In contrast, only 55.3 or 60% of the volume of
a larger (17.0 cm3) tumor that required multiple reposi-
tionings of the applicator could be ablated within
20 min using intraductal or transgastric approaches, re-
spectively. Intraductal hyperthermia was able to treat
relatively large portions (89.9–94.7%) of two small and
medium sized tumors (4.4 & 11.4 cm3). In all cases, sen-
sitive anatomy was kept at temperatures of no more
than 45 °C (Table 4).
Both 360° and sectored transducers were used. To
protect sensitive anatomy while heating in all direc-
tions in order to treat larger volumes, 360° applica-
tors were placed off-center within the tumors, away
from sensitive tissues (Fig. 4), in Cases 4–6. In four
cases, transducers with wide sector angles of 210 or
270 °C carefully directed away from sensitive anatomy
were utilized.
In Case 3, the pancreatic tail tumor was surrounded
by several critical organs, including the right kidney, the
spleen, and the splenic vein. To protect the blood
vessels, a 270° directional applicator was placed adjacent
to the vessels closest to the tumor, and the acoustic en-
ergy was directed away from these vessels (Fig. 5). A
small portion of the tumor in the direction of the non-
active sector was heated through conduction, but there
was little heating penetration in the non-active direction,
and minimal heating in the direction of the nearby ves-
sels. To avoid renal heating, the applicator was placed
perpendicular to the kidney surface, though not deep
enough to puncture it, so that the well-collimated acous-
tic beam would not enter the kidney.
In Case 7 the duodenum, renal vein, and vena cava
were located in close proximity to a tumor in the head
of the pancreas, with the duodenum on the right side of
the tumor and these two vessels immediately posterior
to the tumor (Fig. 6). As directional heating could not
be applied to direct all heat away from both of these
structures without leaving significant portions of the
tumor untreated, this case was modeled using only
hyperthermia and a 360° applicator. 97.3% of the tumor
volume was heated to a target temperature of 40 °C or
higher, with a maximum tumor temperature of 47.1 °C
near the applicator. The maximum temperatures on
nearby sensitive anatomy were 42.9, 39.7, 38.7, 37.8, and
37.3 °C in the duodenum, blood vessels, bone, liver, and
kidney, respectively.
Both transgastric and intraductal approaches were
considered to treat a large (4.8 cm long) tumor in the
head of the pancreas. As the stomach and major vessels
were very close to the tumor, 270° sectored applicators
were employed to minimize energy directed towards
these sensitive tissues. To cover this tumor, the applica-
tor, which contained two 10 mm transducers, was
inserted to two depths for both approaches, and rotated
to 1–2 positions at each depth. There were a total of 3–
4 applicator positions and rotations over the course of
each of the transgastric and intraductal ablations. To
provide additional cooling for both approaches, the
stomach was assumed to have been filled with 22 °C
water before the start of the first ablations, in which the
Table 4 Maximum temperature (°C) in tumors and the sensitive anatomy modeled in the eight cases considered
Case Treatment Tumor Duodenum Stomach Blood vessels Liver Kidney Bone Spleen Intestine
1 Ablation 83.6 N/A 44.6 44.7 N/A N/A N/A N/A N/A
2 Ablation 84.4 N/A 43.2 45.0 N/A N/A N/A N/A N/A
3 Ablation 84.5 N/A 40.5 44.3 N/A 43.3 N/A 40.5 N/A
4 Hyperthermia 47.1 38.0 37.6 39.0 37.1 N/A 37.4 N/A N/A
5 Ablation 80.1 40.0 38.3 44.6 37.2 N/A 38.0 N/A N/A
6 Ablation 79.8 44.7 37.4 39.2 37.4 N/A N/A N/A 38.1
7 Hyperthermia 47.1 42.9 37.1 39.7 37.8 37.3 38.7 N/A N/A
8 Ablation 80.1 42.6 37.1 42.5 N/A 37.0 38.1 N/A N/A
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applicator was placed closest to the stomach wall.
Hyperthermia was not performed in this case because
treatment at 4 discrete positions for 30–60 min each
would take an unreasonable amount of time. The
transgastric approach, employing 3 applicator positions,
allowed for 10.2 cm3 of the 17.0 cm3 tumor to be ablated
over 20 min, with maximum stomach and blood vessel
temperatures of 44.7 and 44.6 °C, respectively (Fig. 7).
The intraductal approach, employing 4 discrete applica-
tor positions, allowed for 9.4 cm3 of the 17.0 cm3 tumor
to be ablated over 30 min, with maximum stomach and
blood vessel temperatures of 43.2 and 45.0 °C,
respectively.
Parametric studies of preservation of blood vessels
A simulated parametric study was performed to deter-
mine the effects of errors in the estimated heat transfer
coefficient on calculated heating of blood vessels.
Figure 8 shows the maximum temperatures on the inner
and outer surfaces of blood vessels of various sizes after
10 min of heating, for a variety of heat transfer coeffi-
cients and distances between the transgastric applicator
and the blood vessels. For a wide margin of error, that
the heat transfer coefficients are at least 25% of the esti-
mated values, acoustic energy can be directed at blood
vessels provided that the applicator is positioned at least
15.8 mm from the vena cava, 15.1 mm from the aorta,
14.4 mm from large blood vessels such as the portal
vein, or 13.4 mm from small blood vessels such as the
superior mesenteric artery, assuming that maximum tis-
sue temperatures are limited to 80 °C. Using the esti-
mated heat transfer coefficients without a margin of
error, the applicator should be positioned at least
14.8 mm from the vena cava, 13.9 mm from the aorta,
Fig. 4 3D images showing placement of applicator off-center within tumor to avoid heating of the duodenum (Case 6). a Map of temperatures
on the tumor, duodenum, stomach, and blood vessels. b 52 °C contour shown relative to the positions of the tumor, duodenum, and stomach
Fig. 5 a 3D rendering of the anatomy in Case 3, showing the position of the vessels, kidney, and spleen around the tumor. b Map of
temperature on tumor and blood vessel surfaces, with the 52 °C contour (red) and the 270 °C applicator shown
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12.0 mm from large blood vessels, and 9.4 mm from
small blood vessels.
Blood vessel temperatures were more sensitive to
changes in the heat transfer coefficient when the appli-
cator was closer to the vessels. Changes in heat transfer
coefficients also had a larger effect on temperatures in
smaller vessels than larger vessels, and this effect was
more pronounced on the outer surface on the vessels.
As expected, vessel temperatures were higher when the
applicator was closer to the vessel, with an exception in
Fig. 6 a 3D image of anatomy showing position of tumor between vena cava and duodenum (Case 7), with several organs not shown for clarity.
b 2D map of temperatures during intraductal hyperthermia treatment. Superior mesenteric artery is abbreviated SMV
Fig. 7 a 3D image of anatomy showing position of large tumor (Cases 1&2) between the stomach wall and several major blood vessels (white).
b-d Axial 2D maps of temperatures at the end of ablations at each of three position of the transgastric applicator (Case 1)
Scott et al. Journal of Therapeutic Ultrasound  (2017) 5:10 Page 10 of 16
some cases with low heat transfer coefficients when the
applicator was close enough (<4 mm) for catheter cool-
ing to play a role.
Parametric study of duodenal heating
A parametric study was performed to determine the
treatment parameters necessary for preservation of the
duodenum. The maximum temperature on the duode-
num for 360° and 270° applicators 2–30 mm from the
duodenum is plotted in Fig. 9, with treatment times of 5
and 10 min and initial temperatures of 22 and 37 °C.
The distance from the applicator to the duodenum
and the sector size of the applicator had more
pronounced effects on the maximum duodenum tem-
perature than initial temperature or treatment time.
Use of a 270° applicator aimed directly away from the
duodenum decreases the duodenal temperatures up to
21.1 °C when compared to a 360° applicator for a
10 min ablation. A 360° applicator parallel to the
duodenum would have to be positioned at least
14 mm from the duodenum to avoid damage (<45 °C)
after 10 min of ablation, assuming an initial
temperature of 37 °C. A 270° applicator, however,
could be placed 7 mm from the duodenum under the
same conditions.
Reducing the treatment time from 10 to 5 min had
only a moderate effect on duodenal temperatures for
360 °C applicators, with maximum duodenal tempera-
tures decreasing by at most 4.1 °C. For 270° applicators,
this reduction in treatment time had even less effect,
with a change in maximum duodenal temperatures of
only 1.7 °C at most.
Filling of the duodenum with 22 °C cooling water
prior to treatment had a negligible effect on the max-
imum duodenum temperature at the end of 10 min
treatments with 360° applicators and treatments of 5
or 10 min with 270° applicators directed away from
the duodenum. With short treatment times using
360° applicators, the initial cooling has a small effect.
Cooling reduced the maximum duodenum tem-
perature by 2.1 °C or less after 5 min treatments with
360° applicators, and only 1.3 °C or less after 10 min
treatments with 360° applicators. For 270° applicators
directed away from the duodenum, duodenal cooling
reduced the maximum duodenum temperature by
only 1.0 and 0.4 °C after 5 and 10 min treatments,
respectively.
Fig. 8 Maximum temperature on the outer (solid) and inner (dashed) surfaces of blood vessels after 10 min of heating, as a function of distance
from the applicator to the outer surface of the blood vessel, for a variety of heat transfer coefficients. The temperature of the aorta is given in (a),
the temperature of large 13.0 mm OD vessels is given in (b), and the temperature of small 5.8 mm OD vessels is given in (c)
Fig. 9 The maximum temperature of the duodenum (°C) when
heated by a 360° applicator or a 270° applicator directed away from
the duodenum, as a function of distance from the applicator to the
duodenum, for 5 and 10 min treatment times and for initial
temperatures of the duodenal lumen of 22 °C and 37 °C
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Parametric study of absorption and perfusion
The thermal lesion diameter that can be attained after
10 min of heating with transgastric and intraductal ap-
plicators is plotted in Fig. 10 for a variety of acoustic at-
tenuation coefficients and blood perfusion rates.
Assuming a tumor attenuation of 68 Np/m and perfu-
sion of 4.5 kg/m3/s (Table 1), this study indicated that
pancreatic tumors up to 2.5 or 2.7 cm diameter can be
ablated within 10 min using the transgastric and intra-
ductal approaches, respectively. Intraductal applicators
produced slightly larger (1.1–2.5 mm in diameter) ther-
mal lesions than transgastric applicators, particularly in
tissues with lower attenuations. Variations in blood per-
fusion rates generally had more pronounced effects on
thermal lesion diameters than did variations in acoustic
attenuation coefficients. Variations in acoustic attenu-
ation had a greater effect on lesion sizes at lower blood
perfusion rates than at higher rates.
Discussion
This study was performed to provide a broad and pre-
liminary investigation of the feasibility of transgastric
and intraductal approaches to ultrasound-based thermal
therapy of pancreatic tumors. Such an approach would
provide localized directionality of heating which RF,
microwave, and laser ablation lack, without the acoustic
window limitations faced by HIFU. Through patient spe-
cific modeling and parametric studies we have demon-
strated that this technology would have the ability to
treat tumors positioned > 4–5 cm from the gastrointes-
tinal (GI) tract, which ultrasound applicators sonicating
from within the tract cannot access. Patient-specific
simulations herein have demonstrated the ability of
transgastric and intraductal ultrasound to generate
therapeutic temperature distributions within the major-
ity of the volumes of pancreatic tumors without damage
to sensitive structures. Further, parametric studies iden-
tified appropriate treatment parameters for a variety of
settings to avoid thermal damage to the duodenum or
major blood vessels, and to identify limitations of the
technology.
Sensitive tissues can be protected through careful
placement of the applicator and through the use of sec-
tored applicators. Guidance of applicator placement may
be achieved clinically through MR, CT, ultrasound, or
fluoroscopic guidance. Needle-based temperature probes
or MR temperature imaging could be applied to confirm
correct placement and to ensure that sensitive tissues
are not overheated. To prevent overheating in the direc-
tion of non-targeted anatomy, transducers with wide
sector angles (210° or 270°) were employed in four
patient-specific simulations. Wide sector angles allow for
heating of large tumor volumes, and only limited heating
dominated by conduction occurs in the direction of the
sensitive structures. Sectored applicators can be posi-
tioned closer to sensitive anatomy than 360° applicators,
with the emitted energy directed away from these or-
gans. Filling the duodenum with cold water prior to
treatment was not found to be a highly effective means
of tissue protection, reducing the duodenal temperature
by 2.1 °C or less (Fig. 9). Without active cooling of the
duodenum, 360° applicators can be placed 14 mm, and
directional applicators can be placed 7 mm, from the
duodenal wall without damaging the tissue over the
course of a 10 min treatment. The high blood perfusion
rates in the duodenum, as well as the relatively high wall
thickness considered in order to simulate a worst case
scenario, may have contributed to this result.
Applicator placement was determined based on the
tumor shape and the location of sensitive structures. In
most cases, the applicator was placed in the center of
the target volume. If possible, the applicator axis was
aligned with the long axis of the tumor, as the ablated
zone has the shape of an ellipsoid with the long axis
aligned with the applicator. In cases where sensitive
anatomy is to one side of the tumor, the applicator could
be placed either perpendicular to and outside the surface
of the sensitive structure, such that the well-collimated
acoustic output does not enter it (Case 8), or off-center
within the tumor, similar to the 360° applicator posi-
tioned away from sensitive tissues in Case 6 (Fig. 4). An
ultrasound applicator can be placed closer to blood ves-
sels, which are self-cooling due to blood flow, than to
Fig. 10 The maximum thermal lesion diameter (T > 52 °C) after
10 min of heating as a function of tissue attenuation, for a variety
of blood perfusion rates for both transgastric (solid lines) and
intraductal (dashed lines) applicators
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organs, as can be seen by comparing Figs. 8 and 9. Our
finding that a 360° ultrasound applicator should be
placed at least 12 mm from large blood vessels like the
portal vein is in accordance with a study by Wu et al.
[53]. They found that 5 mm is an insufficient safety mar-
gin between an RFA site and major peripancreatic ves-
sels, namely the portal vein, in this study in which three
deaths were caused by portal vein thrombosis followed
by massive gastrointestinal hemorrhage [53].
The selection of either a transgastric or intraductal ap-
proach can be decided based on the size and location of
the tumor. A transgastric approach can be used in cases
with an available route from the stomach or duodenum
that does not transverse major blood vessels or sensitive
tissues. Depending on the size of the duodenum and the
constriction and distance from the pyloric sphincter,
attaining the desired insertion angle may be easier from
the stomach, where there is greater freedom of motion,
than from the duodenum. An intraductal approach is
more appropriate for tumors near the head of the pan-
creas that can be accessed from and are immediately adja-
cent to or encapsulating the pancreatic duct. The
intraductal approach can ablate slightly larger volumes
than the transgastric approach (26.8 mm vs. 25.4 mm
diameter, assuming 4.5 kg/m3/s perfusion and 68 Np/m
attenuation). For tumors partially encapsulating the duct,
directional sectored applicators may be more appropriate,
but they produce much smaller ablated volumes.
The intraductal approach is less invasive than the
transgastric one, as it does not require any penetration
through the stomach or duodenal wall. Although other
transgastric interventions are being investigated with lar-
ger instruments than the transgastric ultrasound applica-
tors presented herein [54], less invasive procedures are
generally preferable when possible, thus making the
intraductal approach more attractive when feasible.
However, the full target volume must be accessible
(<1.2 cm for ablation from applicator to outer target
boundary) from the pancreatic or bile duct. The size of
the duct may potentially limit some intraductal treat-
ments to tumors near the head of the pancreas, which is
acceptable, as about 70–85% of pancreatic tumors arise
in the head [6]. Procedures commonly used for dilata-
tion and placement of stents could be applied during the
placement of the ultrasound device.
Hyperthermia for the treatment of pancreatic cancer,
as an adjunct to radiation therapy, chemotherapy, im-
munotherapy, or nanoparticle drug delivery, has poten-
tial clinical utility. The feasibility of low temperature
heating or hyperthermia delivery is largely dependent on
the tumor size and location. Hyperthermia can be
applied using the less invasive intraductal approach, fol-
lowing procedures commonly used for pancreatic stent-
ing. Large tumors requiring multiple applicator positions
are inappropriate for hyperthermia, as treatment at each
position would require 30–60 min. Hyperthermia also
has all the limitations associated with the intraductal ap-
proach, including less flexibility in selection of applicator
positions than the transgastric approach. Hyperthermia
may be preferred over ablation for moderately sized tu-
mors with sensitive anatomy on multiple sides of the
tumor, as in Case 7, where sensitive tissues could not be
readily protected solely by the use of directional
transducers.
Larger proportions of tumor volumes were treated
with hyperthermia (89.9–94.7%) than with ablation
(55.3–83.3%) in this study. This may be due in part to
the lower risk of thermal injury to sensitive tissues dur-
ing hyperthermia placing fewer limitations on treatment,
and to the selection of tumors small enough for treat-
ment with a single applicator position. Because hyper-
thermia uses inherently lower and safer temperatures
than ablation, larger proportions of tumor volumes can
be treated with less heating of nearby sensitive tissues.
When planning treatments of pancreatic tumors, the
attenuation coefficients of the tumor tissue and desmo-
plastic stroma should be taken into consideration in
order to optimize treatment parameters. Parametric
studies demonstrate the significant effect tissue attenu-
ation rates have on the size of the ablated region, espe-
cially in cases with low blood perfusion rates (Fig. 10).
Pancreatic ductal adenocarcinoma, a common form of
pancreatic cancer, is known to exhibit extensive and het-
erogeneous fibrosis [55, 56]. Fibrous tissues generally
have higher attenuation coefficients than other soft tis-
sues [52], which could result in preferential heating of
the desmoplastic stroma nearest the applicator, and less
acoustic propagation through the stroma into the tumor.
This could possibly result in reduced heating of both the
portion of the tumor further from the applicator, and
any sensitive anatomy. A study to obtain measurements
of tissue properties for pancreatic tumor samples, as re-
lated to their fibrous content and appearance under
diagnostic medical imaging, would be extremely useful
in informing further development of ultrasound-based
therapeutic strategies for pancreatic cancer. Both attenu-
ation coefficients, and the distribution of desmoplastic
stroma in and around the targeted tumor, should be
taken into account when planning treatments.
The favorable findings of this exploratory study, al-
though preliminary, indicate that further investigation of
these approaches for delivering ultrasonic or thermal
therapies for the treatment of pancreatic cancer is
warranted. The pathway for additional development to-
ward clinical implementation could include the design,
fabrication, and experimental evaluations of intraluminal
and transgastric devices specific for the pancreas.
Specific image guidance approaches, such as MRI with
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non-invasive temperature monitoring [57–59], or ultra-
sound or CT imaging with electromagnetic tracking
[60–62], could be integrated as a means to precisely pos-
ition and verify therapy delivery. Incorporation of
optimization-based patient specific treatment planning
[39, 63, 64] could be applied for a priori or real-time de-
termination of ideal positioning, applicator selection,
and applied power trajectories. This could include
model-based feedback treatment control, to optimally
determine parameters for conformal targeting and en-
suring adequate safety zones. Detailed and extensive in
vivo studies in large animals could be performed to
characterize thermal dosimetry, to closely evaluate heat-
ing around ducts and vessels, to define limitations and
safety information, to provide feedback to designs and
monitoring approaches, and to validate guidance and
planning as above. Given successful development within
this framework, precise delivery of safe and conformal
hyperthermia or thermal ablation of target regions
within the pancreas can possibly be delivered in a
minimally-invasive fashion, thereby providing a superior
alternative to other invasive modalities in regions where
extracorporeal HIFU may not be practicable.
Conclusion
This study has demonstrated the feasibility of ablation of
2.5 cm diameter targets in the pancreas using transgas-
tric and intraductal ultrasound applicators, provided that
there is sufficient separation of sonicated regions from
sensitive organs and blood vessels. To preserve sensitive
structures, 360° applicators should be placed at least
13.9–14.8 mm from major vessels like the aorta or vena
cava, 9.4–12.0 mm from other sizable vessels, and
14 mm from the duodenum. Alternatively, sectored
transducers can be positioned closer to sensitive anat-
omy, with the emitted energy directed away from these
structures. In cases with tumors near or encapsulating
the pancreatic duct, intraductal hyperthermia may pro-
vide a therapy option in conjunction with radiation or
chemotherapy.
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